Plasma metabolomic and lipidomic alterations associated with COVID-19

Wu, Di; Shu, Ting; Yang, Xiaobo; Song, Jin Yeong; Zhang, Mingliang; Yao, Chengye; Li, Wen; Huang, Mingbin; Yuan, Yu; Yang, Qingyu; Zhu, Tingju; Xu, Jiqian; Mu, Jian; Wang, Yaxin; Wang, Hong; Tang, Tang; Ren, Yujie; Wu, Yongran; Lin, Shuhai; Qiu, Yang; Zhang, Ding-Yu; Shang, You; Zhou, Xi

doi:10.1093/nsr/nwaa086

Cited by 278 publications

(339 citation statements)

References 23 publications

Supporting

Mentioning

309

Contrasting

Unclassified

Order By: Relevance

“…Previous studies have reported that lipid metabolism impairment may be involved in the pathogenesis of sepsis secondary to pneumonia and in uenza [8][9][10]. Similarly, recent studies observed dyslipidemia in patients infected with SARS-CoV-2, using MS analysis [6,7] and routine laboratory lipid tests [11], indicating that blood lipid might involve in the pathogenesis of COVID-19. In the study of Wei et al [11], a serum hypolipidemia was found in the COVID-19 patients, which showed that the serum level of TC, HDL-C and LDL-C in the patients with COVID-19 were signi cantly lower than healthy subjects, especially in the severe and critical cases.…”

Section: Discussionmentioning

confidence: 91%

“…Consequently, some clinical characteristics, the in ammation index and cytokine levels have been used as indictors to re ect the severity of COVID-19 by us and others [4,5]. Recently, emerging evidence suggested that lipid metabolism dysregulation might promote the progression of COVID-19 as revealed by mass spectrometry (MS)-based proteomics analysis [6,7]. Although MS analysis is not commonly performed, blood lipid is routinely examined using automatic biochemical instruments in clinical laboratories.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Preliminary Study on Blood Lipid Profile in Patients with COVID-19

Zhu

Yang

Fan

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Recently, dyslipidemia was observed in the patients with coronavirus disease 2019 (COVID-19). This study aimed to investigate the blood lipid profile in the patients with COVID-19, and explore their predictive value for COVID-19 severity.Methods: 142 consecutive patients with COVID-19 admitted to HwaMei Hospital, University of Chinese Academy of Sciences, from January 23 to April 20, 2020, and 77 age- and gender-matched healthy subjects were included in this retrospective study. The blood lipid profile in the patients with COVID-19 were investigated, and their predictive values for COVID-19 severity were analysed.Results: There were 125 and 17 cases in the non-severe and severe group, respectively. Total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein A1 (ApoA1) gradually decreased across healthy controls, non-severe group, and severe group. ApoA1 was recognized as an independent risk factor for COVID-19 severity，and had the highest area under the receiver operator characteristic curve (AUC) among all the single markers (AUC: 0.896, 95% CI: 0.834-0.941). Moreover, the risk model established using ApoA1 and IL-6 enhanced the prediction efficiency (AUC: 0.977, 95% CI: 0.932-0.995). Conclusion: The blood lipid profile in the patients with COVID-19 is quite abnormal from healthy subjects, especially in the severe cases. Serum ApoA1 might serve as a good indictor to reflect the severity of COVID-19.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Introductionmentioning

confidence: 99%

A Preliminary Study on Blood Lipid Profile in Patients with COVID-19

Zhu

Yang

Fan

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…In clinical medicine, serum albumin can be measured via standard serum laboratory testing that measures both free and bound albumin. Free fatty Acids (FFA), melatonin (2,(48)(49)(50) and the SARS-CoV-2 virions are transported bound to albumin as are glycolates. Studies on drug interactions confirm both competitive and non-competitive binding (49,(51)(52)(53)(54).…”

Section: Human Serum Albuminmentioning

confidence: 99%

SARS-CoV-2 Bound Human Serum Albumin and Systemic Septic Shock

Johnson

Fatemi

Winlow

2020

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

The emergence of the COVID-19 virus and the subsequent pandemic have driven a great deal of research activity. The effects of COVID-19 are caused by the severe respiratory syndrome coronavirus 2 (SARS-CoV-2) and it is the underlying actions of SARs-CoV-2 virions on the endothelial glycocalyx that we consider here. One of the key factors in COVID-19 infection is its almost unique age-related profile, with a doubling in mortality every 10 years after the age of 50. The endothelial glycocalyx layer is essential in maintaining normal fluid homeostasis, but is fragile and prone to pathophysiological damage. It is physiologically significant in capillary microcirculation and in fluid distribution to the tissues. Human serum albumin (HSA), the most abundant protein in plasma, is created in the liver which also maintains its concentration, but this reduces by 10-15% after 50 years of age. HSA transports hormones, free fatty acids and maintains oncotic pressure, but SARS-CoV-2 virions bind competitively to HSA diminishing its normal transport function. Furthermore, hypoalbuminemia is frequently observed in patients with such conditions as diabetes, hypertension, and chronic heart failure, i.e., those most vulnerable to SARS-CoV-2 infection. Hypoalbuminemia, coagulopathy, and vascular disease have been linked in COVID-19 and have been shown to predict outcome independent of age and morbidity. Hypoalbuminemia is also known factor in sepsis and Acute respiratory distress syndrome (ARDS) occurs when fluids build-up in the alveoli and it is associated with sepsis, whose mechanism is systemic, being associated with the fluid and logistic mechanisms of the circulation. Glycocalyx damage is associated with changes plasma protein concentration, particularly HSA and blockage of albumin transport can produce the systemic symptoms seen in SARS-CoV-2 infection and sepsis. We therefore conclude that albumin binding to SARS-CoV-2 virions may inhibit the formation of the endothelial glycocalyx by inhibition of albumin transport binding sites. We postulate that albumin therapy to replace bound albumin might alleviate some of the symptoms leading to sepsis and that clinical trials to test this postulation should be initiated as a matter of urgency.

show abstract

“…Previous studies have reported that lipid metabolism impairment may be involved in the pathogenesis of sepsis secondary to pneumonia and in uenza [9][10][11]. Similarly, recent studies observed dyslipidaemia in patients infected with SARS-CoV-2, especially in the severe cases, using MS analysis, [6][7][8], indicating that blood lipids might serve as a marker of COVID-19 severity. Among the altered lipids, ApoA1 was signi cantly decreased.…”

Section: Discussionmentioning

confidence: 87%

“…Consequently, some clinical characteristics, the in ammation index and cytokine levels have been used as indictors to re ect the severity of COVID-19 by us and others [4,5]. Recently, emerging evidence suggested that lipid metabolism dysregulation might promote the progression of COVID-19 as revealed by mass spectrometry (MS)-based proteomics analysis [6][7][8]. Although MS analysis is not commonly performed, blood lipids are routinely examined using automatic biochemical instruments in clinical laboratories.…”

Section: Introductionmentioning

confidence: 99%

Low serum apolipoprotein A 1 is an indicator of severity in patients with coronavirus disease 2019

Yang

Zhu

Fan

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Recently, dyslipidaemia was observed in patients with coronavirus disease 2019 (COVID-19), especially in severe cases. This study aimed to explore the predictive value of blood lipid levels for COVID-19 severity.Methods: All patients with COVID-19 admitted to HwaMei Hospital, University of Chinese Academy of Sciences, from January 23 to April 20, 2020, were included in this retrospective study. General clinical characteristics and laboratory data (including blood lipid parameters) were obtained, and their predictive values for the severity were analysed.Results: In total, 142 consecutive patients with COVID-19 were included. The non-severe group included 125 cases, and 17 cases were included in the severe group. Total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein A1 (ApoA1) at baseline were significantly lower in the severe group. ApoA1 and interleukin-6 (IL-6) were recognized as independent risk factors for COVID-19 severity. ApoA1 had the highest area under the receiver operator characteristic curve (AUC) among all the single markers (AUC: 0.896, 95% CI: 0.834-0.941). Moreover, the risk model established using ApoA1 and IL-6 enhanced the predictive value (AUC: 0.977, 95% CI: 0.932-0.995). On the other hand, ApoA1 levels were elevated in the severe group during treatment, and there was no significant difference between the severe and non-severe groups during the recovery stage of the disease.Conclusion: The blood lipid profile in severe COVID-19 patients is quite different from that in non-severe cases. Serum ApoA1 could severe as a good indictor to reflect the severity of COVID-19.

show abstract

Plasma metabolomic and lipidomic alterations associated with COVID-19

Cited by 278 publications

References 23 publications

A Preliminary Study on Blood Lipid Profile in Patients with COVID-19

A Preliminary Study on Blood Lipid Profile in Patients with COVID-19

SARS-CoV-2 Bound Human Serum Albumin and Systemic Septic Shock

Low serum apolipoprotein A 1 is an indicator of severity in patients with coronavirus disease 2019

Contact Info

Product

Resources

About